3 results
Approved WMOCompleted
To evaluate the efficacy of Lanreotide Autogel 120 mg when used as primary medical treatment in untreated de novo acromegalic patients with macroadenoma
Approved WMOCompleted
The purpose of this study is to look at the effect of changing from monthly (4 weekly) injections of your usual treatment (octreotide LAR) to less frequent treatment (once every 6 or 8 weeks) with lanreotide Autogel 120 mg injections. The study…
Approved WMOPending
The main objective of the trial is to show that ABVD-based response-adapted therapy for advanced-stage Hodgkin lymphoma, with treatment intensification (BEACOPP) in case of a positive FDG-PET after one cycle of ABVD, has non-inferior efficacy…